WHO spearheads NICE (UK National Institute for Clinical Excellence) reviews
This article was originally published in Clinica
Two major reviews of the work of the UK's National Institute for Clinical Excellence (NICE) got underway this week. The World Health Organization (WHO) has been invited to conduct a "robust and objective" assessment of NICE's technology appraisals programme. The WHO's review coincides with the institute's own scheduled three-year review of the process and methodologies used to develop technology appraisals guidance.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.